XVIVO appoints a new IP manager and a new Medical Director
Anne-Li Sigvardsson, MSc has been appointed Chief Intellectual Property Officer (CIPO). Anne-Li is responsible for the company's IP portfolio and has developed XVIVO's patent portfolio for PrimECC and Perfadex Plus, among other products. Andreas Wallinder, MD, PhD has been appointed Chief Medical Officer (CMO). Andreas is the indication leader for the company's heart preservation development and also clinically responsible within the company.Anne-Li Sigvardsson has a MSc in chemical engineering and has worked with research and development in the medical technology field for more than 20